Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2024 | PERSIAN: apalutamide and metastases-directed SBRT in mHSPC

Giulio Francolini • 25 Jan 2024

GU Cancers 2024

PERSIAN

Giulio Francolini, MD, University of Florence, Florence, Italy, provides an overview of the Phase II PERSIAN trial (NCT05717660) of apalutamide and metastases-directed stereotactic body radiation therapy (SBRT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) with oligometastases. The trial, excluding de novo metastatic cases, will assess the benefit of SBRT in a cohort receiving apalutamide and androgen deprivation therapy. Primary endpoints include the 6-month rate of complete biochemical response. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.